← All trials
NCT04461041
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2020
- Primary completion
- Aug 31, 2022
- Completion date
- Dec 31, 2022
- First posted
- Jul 8, 2020
- Last posted
- Jul 8, 2020
- Enrollment
- 164
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TorontoLead sponsor
- University of TorontoOverall official - principal investigator
- Boehringer IngelheimCollaborator
- Applied Health Research CentreCollaborator
- Canadian Medical and Surgical Knowledge Translation Research GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.